This retrospective non - interventional patient chart review will be utilizing real world clinical data from patients treated for rGBM at the University Regensburg Medical center either with or without bevacizumab. Only patients will be analyzed who were potentially eligible for bevacizumab treatment. The study is designed to investigate the potential effects of bevacizumab treatment on the functional status, symptom burden, neurological deficits, time to tumor progression and overall survival between cohorts potentially eligible for bevacizumab.
Study Type
OBSERVATIONAL
Enrollment
203
Observation of neurological deficits
University Hospital Regensburg
Regensburg, Germany
Functional outcome
Neurological deficits impacting functional independency
Time frame: 15 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.